This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report


Na, Hae-Ri, Kim, SangYun, Choi, Seong Hye, Yang, Dong-Won, Bae, Hee-Joon, Kim, Jung-Eun, Park, Mee-Young, Shim, Yong-Soo, Kim, Byung-Kun, Kwon, Jae-Cheol, Yoo, Bong Goo, Kim, Byeong-Chae, Lee, Jung-Seok


Geriatrics & Gerontology International, Volume: 11, No.: 1, Pages.: 90-97

Year of Publication



Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with probable AD of mild to moderate severity. CVL were evaluated through magnetic resonance imaging (MRI) findings within 3 months. Efficacy analyses were performed for cognitive, behavioral and functional outcome measures.; Results: Concomitant CVL were documented in 35 (30.7%) of the patients on MRI. Seventy-nine (69.3%) of the patients were considered not to have concomitant CVL. The mean Mini-Mental State Examination scores of both patients with and without CVL showed improvement at each evaluation. However, there was no statistical difference in improvement between the groups.; Conclusion: The presence of CVL should not deter clinicians from treating AD with donepezil.; © 2010 Japan Geriatrics Society.

Bibtex Citation

@article{Na_2010, doi = {10.1111/j.1447-0594.2010.00649.x}, url = {}, year = 2010, month = {sep}, publisher = {Wiley-Blackwell}, volume = {11}, number = {1}, pages = {90--97}, author = {Hae-Ri Na and SangYun Kim and Seong-Hye Choi and Dong-Won Yang and Hee-Joon Bae and Jung-Eun Kim and Mee-Young Park and Yong-Soo Shim and Byung-Kun Kim and Jae-Cheol Kwon and Bong-Goo Yoo and Byeong-Chae Kim and Jung-Seok Lee}, title = {Donepezil treatment in Alzheimer{textquotesingle}s disease patients with and without cerebrovascular lesions: A preliminary report}, journal = {Geriatrics {&} Gerontology International} }


administration & dosage, aged, aged, 80 and over, alzheimer disease, brain, cerebrovascular disorders, cholinesterase inhibitors, complications, diagnosis, donezepil, drug therapy, female, humans, indans, magnetic resonance imaging, male, middle aged, pathology, piperidines, retrospective studies, therapeutic use, time factors, treatment outcome

Types of Dementia

Alzheimer’s Disease

Type of Outcomes

ADLs/IADLs, Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime